Home
Medilink Therapeutics

Medilink Therapeutics Market Share Analysis for July 2026

medilink therapeutics

Health > Biotechnology and Pharmaceuticals

Domainmedilinkthera.com

Year Founded2020

Employees51 - 200

Annual Revenue$1M - $2M

Medilink Therapeutics

Medilink Therapeutics (including company regionals)

medilinkthera.com

See more website traffic and engagement information

Medilink Therapeutics Revenue up to July 2026 is 1M - 2M

revenue generated by Medilink Therapeutics top domains

Medilink Therapeutics top domains revenue over 3 years

Revenue for Medilink Therapeutics top domains

medilinkthera.com1M - 2M

See more with Sales Intelligence

Total visits to Medilink Therapeutics's top domains

Understand Medilink Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

medilinkthera.com3.3K

See more with Sales Intelligence

Avg. visit duration in Medilink Therapeutics's top domains

Analyze Medilink Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

medilinkthera.com00:00:26

See more with Sales Intelligence

Avg. pageviews on Medilink Therapeutics's top domains

See how Medilink Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

medilinkthera.com1.78

See more with Sales Intelligence

Medilink Therapeutics top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Medilink Therapeutics

These are the website technologies, by industry, used by Medilink Therapeutics top domains

Mobile (3)

Meta Viewport

Content Management System (2)

WordPress

Advertising (1)

PubMatic

Audio Video Media (1)

VideoJS

More Technologies

2

See all

News & Signals from Medilink Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsMedilinkthera is developing antibody-drug conjugate YL201 on Jul 15th '26.In a special section, "Pharma Takes the Lead," the report highlighted how Medilink, leveraging its wholly proprietary and differentiated TMALIN(R) technology platform, successfully developed the antibody-drug conjugate (ADC) YL201 and achieved the world's first positive Phase III results for a B7-H3-targeting ADC.

NewsMedilinkthera attended event Clinical Science Symposium on May 29th '26.MediLink Therapeutics, a clinical-stage biotechnology company focused on next-generation antibody-drug conjugates (ADCs), will present multiple high-profile clinical updates across Clinical Science Symposium, Rapid Oral Presentation, and Poster sessions at this year's meeting, highlighting transformative data from its core oncology pipeline.